natgillin/translations-raw huggingface dataset:
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and for the non-enveloped hepatitis A virus.
Mjere koje se poduzimaju smatraju se učinkovitima za viruse s ovojnicom poput virusa humane imunodeficijencije (HIV), virusa hepatitisa B (HBV), virusa hepatitisa C (HCV) te virusa hepatitisa A bez ovojnice.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A and parvovirus B19 viruses.
Poduzete mjere smatraju se učinkovitim za viruse s ovojnicom poput virusa humane imunodeficijencije (HIV), virusa hepatitisa B i virusa hepatitisa C te za viruse koji nemaju ovojnicu kao što su virus hepatitisa A i parvovirus B19.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A virus and parvovirus B19.
Poduzete mjere smatraju se djelotvornim protiv virusa s ovojnicom kao što su virus humane imunodeficijencije (HIV), virus hepatitis B i C te za viruse bez ovojnice kao što su virus hepatitisa A i parvovirus B19.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A virus.
Poduzete mjere smatraju se učinkovitima za viruse s ovojnicom kao što su virus humane imunodeficijencije (HIV), virus hepatitisa B i virus hepatitisa C te za viruse hepatitisa A bez ovojnice.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A virus.
Smatra se da mjere koje se poduzimaju učinkovito djeluju na viruse s ovojnicom poput virusa humane imunodeficijencije (HIV), hepatitisa B i hepatitisa C te virus hepatitisa A bez ovojnice.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV, the AIDS virus), hepatitis B virus and hepatitis C virus (liver inflammation), and for the non-enveloped hepatitis A virus and parvovirus B19.
Poduzete mjere smatraju se učinkovitima za viruse s ovojnicom kao što su virus humane imunodeficijencije (HIV, virus AIDS-a), virus hepatitisa B i hepatitisa C (upala jetre), te za viruse bez ovojnice kao što su virus hepatitisa A i parvovirus B19V.
The measures taken are considered effective for so-called “enveloped” viruses such as human immunodeficiency virus (HIV, the AIDS virus), hepatitis B virus and hepatitis C virus (which cause inflammation of the liver), and for the “non-enveloped” hepatitis A virus (which also causes inflammation of the liver).
Poduzete mjere smatraju se djelotvornim za takozvane viruse s ovojnicom poput virusa humane imunodeficijencije (HIV, virus AIDS-a), virusa hepatitisa B i hepatitisa C (koji izazivaju upalu jetre) te za viruse hepatitisa A bez ovojnice (koji izaziva upalu jetre).
The measures taken in the manufacture of fibrinogen and thrombin are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped virus, hepatitis A. The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.
Mjere poduzete tijekom proizvodnje fibrinogena i trombina smatraju se djelotvornima za viruse s ovojnicom poput virusa humane imunodeficijencije (HIV), virusa hepatitisa B, virusa hepatitisa C, i virusa hepatitisa A koji je bez ovojnice.
The measures taken in the manufacture of fibrinogen and thrombin are considered effective for lipid coated viruses such as human immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C virus, and the non-enveloped virus, hepatitis A. The measures taken may be of limited value against parvovirus B19.
Mjere koje se poduzimaju u proizvodnji fibrinogena i trombina smatraju se učinkovitima protiv virusa s lipidnom ovojnicom, poput virusa humane imunodeficijencije (HIV), virusa hepatitisa B i hepatitisa C te za viruse bez ovojnice, poput virusa hepatitisa A. Poduzete mjere mogu imati ograničenu djelotvornost protiv parvovirusa B19.
The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.
Poduzete mjere mogu biti ograničene učinkovitosti u borbi protiv virusa bez ovojnice poput parvovirusa B19.
The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.
Poduzete mjere mogu biti ograničene vrijednosti u borbi protiv virusa bez ovojnice poput parvovirusa B19.
The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.
Poduzete mjere mogu imati ograničenu učinkovitost protiv virusa bez ovojnice kao što je parvovirus B19.
The measuring jug in the pack has a line marked to show you an exact amount.
Priložena odmjerna čašica ima oznaku koja će Vam pokazati točnu količinu.
The mechanism and relevance of these findings in the rat carcinogenicity study for humans are not yet clarified.
Iz ovih nalaza studije karcinogenosti u štakora još nije razjašnjen mehanizam, kao ni važnost za ljude.
The mechanism by which Ceplene improves the anti-leukaemic function of lymphocytes in AML is not completely established; it is considered to be by inhibition of reactive oxygen species (ROS or ‘oxygen free radicals’), which are synthesised by monocytes/macrophages and granulocytes.
Mehanizam kojim Ceplene poboljšava antileukemijsku funkciju limfocita u AML-u nije u potpunosti utvrđen; smatra se da djeluje inhibiranjem reaktivnih spojeva kisika (ROS ili “slobodni radikali kisika”), koji se sintetiziraju pomoću monocita/makrofaga i granulocita.
The mechanism by which ribavirin in combination with interferon alfa-2b exerts its effects against HCV is unknown.
Nije poznat mehanizam putem kojega ribavirin u kombinaciji s peginterferonom alfa-2b ili interferonom alfa-2b djeluje na HCV.
The mechanism for this is not known, but as imiquimod has low systemic absorption from human skin, and is not mutagenic, any risk to humans from systemic exposure is likely to be low.
Mehanizam ove pojave nije poznat, ali kako imikvimod ima nisku apsorpciju putem kože i nije mutagen, rizik od sustavne izloženosti vjerojatno je malen.
The mechanism is UGT1A1 inhibition.
Mehanizam je inhibicija UGT1A1.
The mechanism of
Mehanizam interakcije
The mechanism of action by which bimatoprost reduces intraocular pressure in humans is by increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral outflow.
Mehanizam djelovanja kojim bimatoprost snižava očni tlak u ljudi je povećanje istjecanja očne vodice kroz trabekularno tkivo i poboljšanje uveoskleralnog istjecanja.
The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA synthesis.
Mehanizam djelovanja nije još potpuno jasan, ali izgleda da ara-CTP prvenstveno djeluje inhibicijom sinteze DNA.
The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive.
Smatra se da etanercept djeluje mehanizmom kompetitivne inhibicije vezanja TNF-a za TNFR-e na površini stanice čime inaktivira biološko djelovanje TNF-a i tako sprječava stanični odgovor posredovan TNF- om.
The mechanism of action of Holoclar is the replacement of corneal epithelium and lost limbal stem cells in patients in which the limbus has been destroyed by ocular burns.
Mehanizam djelovanja Holoclara je nadomještanje epitela rožnice i izgubljenih limbalnih matičnih stanica u bolesnika u kojih je limbus uništen opeklinama oka.
The mechanism of action of pirfenidone has not been fully established.
Mehanizam djelovanja pirfenidona nije još u potpunosti utvrđen.
The mechanism of action of pirfenidone, the active substance in Esbriet, is not fully understood, but it has been shown to reduce the production of fibroblasts and other substances involved in the formation of hard fibrous tissue during the body’s tissue repair process, thereby slowing down the progression of the disease in IPF patients.
Mehanizam djelovanja pirfenidona, djelatne tvari lijeka Esbriet, nije u potpunosti jasan, no dokazano je da smanjuje stvaranje fibroblasta kao i drugih tvari uključenih u stvaranje tvrdog fibroznog tkiva tijekom postupka zacjeljivanja tjelesnog tkiva, stoga usporava progresiju bolesti u bolesnika s IPF-om.
The mechanism of action of tacrolimus in atopic dermatitis is not fully understood.
Mehanizam djelovanja takrolimusa u atopijskom dermatitisu nije potpuno objašnjen.
The mechanism of eyelash changes and their long term consequences are currently unknown.
Mehanizam promjena na trepavicama i dugoročne posljedice u svezi s tim trenutno nisu poznate.
The mechanism of interaction
Mehanizam interakcije između
The mechanism of interaction between
Mehanizam interakcije između
The mechanism of interaction is
Mehanizam interakcije je
The mechanism of interaction is
Mehanizam interakcije je moguća
The mechanism of interaction is
Mehanizam interakcije nije
The mechanism of interaction is a
Mehanizam interakcije je
The mechanism of interaction is CYP3A4 induction by rifampicin.
CYP3A4 i pokazalo se da
The mechanism of interaction is CYP3A4 inhibition by atazanavir and cobicistat.
Mehanizam interakcije je inhibicija CYP3A4 koju uzrokuju atazanavir i kobicistat.
The mechanism of interaction is CYP3A4 inhibition by atazanavir/ritonavir.
Mehanizam interakcije je inhibicija enzima CYP3A4 atazanavirom i/ili ritonavirom.
The mechanism of interaction is CYP3A4 inhibition by cobicistat.
Mehanizam interakcije je
The mechanism of interaction is CYP3A4 inhibition by cobicistat.
Mehanizam interakcije je inhibicija CYP3A4 koju uzrokuje kobicistat.
The mechanism of interaction is CYP3A4 inhibition by fosamprenavir/ritonavir.
Mehanizam interakcija je inhibicija CYP3A4 fosamprenavirom/ritonavirom.
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2 blockers.
Mehanizam interakcije je smanjenje topljivosti atazanavira s povećanjem želučanog pH zbog H2 blokatora.
The mechanism of interaction is P-gp inhibition by atazanavir and cobicistat.
Mehanizam interakcije je inhibicija P-gp-a koju uzrokuju atazanavir i kobicistat.
The mechanism of resistance identified was FKS1/FKS2 gene mutation.
Mehanizam rezistencije identificiran je kao mutacija gena FKS1/FKS2.
The mechanism of the
Mehanizam interakcije
The mechanism of the interaction has not been completely clarified.
Mehanizam interakcije još uvijek nije u potpunosti razjašnjen.
The mechanism of the LDL lowering effect of simvastatin may involve both reduction of VLDL-C concentration and induction of the LDL receptor, leading to reduced production and increased catabolism of LDL-C.
Mehanizam kojim simvastatin snižava LDL može uključivati i snižavanje koncentracije VLDL kolesterola (VLDL-C) i indukciju LDL receptora, što dovodi do smanjenog stvaranja i pojačane razgradnje LDL-C-a.
The mechanism of this decrease is unknown. (See sections 4.2 and 4.4.)
Mehanizam ovog smanjenja nije poznat. (Vidjeti dijelove 4.2 i 4.4.)
The mechanism of this interaction is CYP3A4 inhibition by atazanavir and cobicistat.
Mehanizam ove interakcije je
The mechanism of this interaction is not clear, but may be the result of transporter inhibition.
Mehanizam te interakcije nije jasan, možda je riječ o inhibiciji prijenosnika.
The mechanism of vasculitis in patients receiving Neulasta is unknown.
Mehanizam nastanka vaskulitisa u bolesnika koji primaju Neulastu nije poznat.
The mechanism, although not proven, may involve a decreased absorption of iodine salts and/or levothyroxine (see section 4.5).
Mehanizam, iako nije dokazan, može uključiti smanjenu apsorpciju soli joda i/ili levotiroksina (vidjeti dio 4.5).
The mechanism, whether immune- and/or non-immune-mediated, by which eptifibatide may induce thrombocytopaenia is not fully understood.
Mehanizam kojim eptifibatid može inducirati trombocitopeniju, bez obzira je li ona imunološki ili ne- imunološki posredovana, nije u potpunosti razjašnjen.
The median (min-max) time since last disease flare was around 7 months (0.0-450 months).
Medijan (minimalno – maksimalno) vremena proteklog od posljednje reaktivacije bolesti bilo je otprilike 7 mjeseci (0,0 – 450 mjeseci).
The median (Q1, Q3) change from baseline in total cholesterol to HDL-cholesterol ratio at Week 96 was 0.1 (-0.3, 0.7) in the E/C/F/TAF group and 0.0 (-0.4, 0.5) in the E/C/F/TDF group (p < 0.001 for the difference between treatment groups).
Medijan (Q1, Q3) promjene omjera ukupnog kolesterola i HDL kolesterola od početne vrijednosti do vrijedosti u 96. tjednu bio je 0,1 (-0,3; 0,7) u skupini liječenoj E/C/F/TAF-om i 0,0 (-0,4; 0,5) u skupini liječenoj E/C/F/TDF-om (p < 0,001 za razliku izmeĎu liječenih skupina).
The median (quartile1, quartile 3) time to achieve haemoglobin correction (≥ 10.0 g/dl and ≥ 1.0 g/dl increase from baseline) was 5 weeks for both once every two week (3, 7 weeks) and once monthly dosing (3, 9 weeks).
Medijan (1. kvartila, 3. kvartila) vremena do postizanja korekcije hemoglobina (povećanje za ≥ 10,0 g/dl i ≥ 1,0 g/dl od početne vrijednosti) iznosio je 5 tjedana kako za doziranje jednom svaka dva tjedna (3, 7 tjedana), tako i za doziranje jednom mjesečno (3, 9 tjedana).
The median (range) lamivudine and zidovudine tmax values were 0.75 (0.50-2.00) hours and 0.50 (0.25- 2.00) hours respectively.
Medijan (raspon) tmax za lamivudin iznosio je 0,75 sata (0,50-2,00), a za zidovudin 0,50 sata (0,25-2,00).
The median (range) lamivudine and zidovudine tmax values were 0.75 (0.50-2.00) hours and 0.50 (0.25-2.00) hours respectively.
Medijan (raspon) tmax za lamivudin iznosio je 0,75 sata (0,50-2,00), a za zidovudin 0,50 sata (0,25-2,00).
The median absolute increase in hepatic fat was 6% after both 26 weeks and 78 weeks of treatment, from 1% at baseline, measured by MRS.
Medijan apsolutnog povećanja masti u jetri bio je 6% i nakon 26 i nakon 78 tjedana liječenja, s tim da je na početku bio 1% , mjereno spektroskopskom metodom nuklearne magnetske rezonancije.
The median age in the multicentre study was 40 years (age range 5 to 73).
Medijan dobi u multicentričnom ispitivanju iznosio je 40 godina (raspon dobi od 5 do 73 godine).
The median age of patients was 61.0 (range: 2584) years.
Medijan dobi bolesnica bio je 61,0 godinu (raspon 25-84 godine).
The median age of subjects was 36 years (range: 19-70).
Medijan dobi ispitanika iznosio je 36 godina (raspon: 19-70).
The median age was 54 years (22% were 65 years); all patients had an ECOG performance score of 0 or 1; and 3 % had history of brain metastases.
Medijan dobi iznosio je 54 godine (22% bolesnika bilo je u dobi  65 godina); svi su bolesnici imali ECOG status 0 ili 1; a 3% bolesnika imalo je moždane metastaze u anamnezi.
The median age was 62 years (range: 21 to 85) with 34% 65 years of age and 7% 75 years of age.
Medijan dobi iznosio je 62 godine (raspon: 21-85), uz 34% bolesnika u dobi od ≥ 65 godina i 7% u dobi od ≥ 75 godina.
The median age was 63 years (range: 39-85) with 44% 65 years of age and 11% 75 years of age.
Medijan dobi iznosio je 63 godine (raspon: 39-85), uz 44% bolesnika u dobi od ≥ 65 godina i 11% u dobi od ≥ 75 godina.
The median age was 66 years (range 37 to 91); 57% of patients were older than 65 years; 60% of patients were male; Whites comprised 84% of the study population, Asians 10%, and blacks 4%.
Medijan dobi iznosio je 66 godina (raspon: 37 – 91); 57% bolesnika bilo je starije od 65 godina; 60% bolesnika bili su muškarci; bijelci su činili 84% ispitivane populacije, Azijati 10%, a crnci 4%.
The median age was 68 years (range, 34; 88), 74% were male and 87% were Caucasian.
Medijan dobi bio je 68 godina (raspon, 34; 88), 74% bili su muškarci, a 87% bilo je bijele rase.
The median age was 68 years (range: 61 to 74) with 64.0% of subjects over 65 years; 71.3% were male, and 84.3% were white; 63.6% had a Rai stage of III or IV, and 58.2% had Binet Stage C. Most subjects had adverse cytogenetic prognostic factors: 39.5% had a 17p chromosomal deletion and/or TP53 mutation, and 78.5% had unmutated genes for IGHV.
Medijan dobi iznosio je 68 godina (raspon: 61-74), sa 64,0% ispitanika starijih od 65 godina; 71,3% muškaraca i 84,3% bijelaca; 63,6% imalo je Rai stadij III ili IV, a 58,2% imalo je Binet stadij C. Većina ispitanika imala je nepovoljne citogenetske prognostičke faktore: 39,5% imalo je 17p kromosomsku deleciju i/ili mutaciju TP53 te je 78,5% imalo nemutirane gene za IGHV.
The median age was 69 years (range 41-92) and the racial distribution was 93% Caucasian, 4% Black, 1% Asian, and 2% Other.
Medijan dobi iznosio je 69 godina (raspon 41-92), a rasna raspodjela bila je 93% bijelaca, 4% crnaca, 1% azijata i 2% drugih rasa.
The median age was 7.3 years (range: 1 t o 17.6 y ears) and the median daily dose of stiripentol was 45.4 mg/kg/day (range: 27.1 to 89.3 mg/kg/day) received in two or three divided doses.
Medijan dobi je bio 7,3 godine (raspon: 1 do 17,6 godina), a medijan dnevne doze stiripentola je bio 45,4 mg/kg/dan (raspon: 27,1 do 89,3 mg/kg/dan) primijenjen u dvije ili tri razdijeljene doze.
The median age was 71 years (range 42-93) and the racial distribution was 77% Caucasian, 10% Asian, 2% Black and 11% other or unknown races.
Medijan dobi iznosio je 71 godinu (u rasponu 42-93), a distribucija prema rasi bila je 77% bijele rase, 10% azijati, 2% crne i 11% druge ili nepoznate rase.
The median age was 71 years (range: 47 to 92) with 78.2% of subjects over 65 years; 65.5% were male, and 90.0% were white; 64.1% had a Rai stage of III or IV, and 55.9% had Binet Stage C. Most subjects had adverse cytogenetic prognostic factors: 43.2% had a 17p chromosomal deletion and/or tumour protein 53 (TP53) mutation, and 83.6% had unmutated genes for the immunoglobulin heavy chain variable region (IGHV).
Medijan dobi ispitanika iznosio je 71 godinu (raspon: 47-92) sa 78,2% ispitanika starijih od 65 godina; 65,5% muškaraca i 90,0% bijelaca; 64,1% imalo je Rai stadij III ili IV, a 55,9% Binet stadij C. Većina ispitanika imala je nepovoljne citogenetske prognostičke faktore: 43,2% imalo je 17p kromosomsku deleciju i/ili mutaciju tumorskog proteina 53 (TP53) te je 83,6% imalo nemutirane gene za promjenjivu domenu teškog lanca imunoglobulina (IGHV).
The median age was 77 years and the median creatinine clearance was 61 mL/min.
Medijan dobi je bio 77 godina, a medijan klirensa kreatinina je bio 61 ml/min.
The median average dose per injection to treat a bleeding episode was 46.07 (interquartile range 32.86-57.03) IU/kg.
Medijan prosječne doze po injekciji za liječenje epizode krvarenja iznosio je 46,07 (interkvartilni raspon: 32,86-57,03) IU/kg.
The median average dose per injection to treat a bleeding episode was 63.51 (interquartile range, 48.92-99.44) IU/kg.
Medijan prosječne doze po injekciji za liječenje epizode krvarenja iznosio je 63,51 (interkvartilni raspon, 48,92-99,44) IU/kg.
The median average weekly dose for splenectomised patients was 3 µg/kg and for non-splenectomised patients was 2 µg/kg.
Medijan prosječne tjedne doze u splenektomiranih bolesnika bio je 3 µg/kg, a u nesplenektomiranih 2 µg/kg.
The median average weekly dose of ALPROLIX was 59.40 IU/kg (interquartile range, 52.95 to 64.78 IU/kg) for subjects <6 years of age and 57.78 IU/kg (interquartile range, 51.67 to 65.01 IU/kg) for subjects 6 to <12 years of age.
Medijan prosječne tjedne doze lijeka ALPROLIX iznosio je 59,40 IU/kg (interkvartilni raspon od 52,95 do 64,78 IU/kg) u ispitanika < 6 godina te 57,78 IU/kg (interkvartilni raspon od 51,67 do 65,01 IU/kg) u ispitanika u dobi od 6 do <12 godina.
The median baseline CD4+ cell count was 352 cells/mm3 (range: 1-1455) and 16.9% had CD4+ cell counts 200 cells/mm3.
Medijan početnog broja CD4+ stanica iznosio je 352 stanica/mm3 (raspon: 1-1455), a 16,9% ispitanika imalo je broj CD4+ stanica od 200 stanica/mm3.
The median baseline plasma HIV-1 RNA was 3.9 log10 copies/ml, and the median baseline CD4 cell count was 385 x 106 cells/l.
Medijan početne vrijednosti HIV-1 RNK u plazmi bio je 3,9 log10 kopija/ml, a medijan početnog broja CD4 stanica bio je 385 x 106 stanica/l.
The median baseline plasma HIV-1 RNA was 4.8 log10 copies per mL, and the median baseline CD4+ cell count was 414 x 106 cells/l (range: 25 to 983 x 106 cells/l).
Medijan početne vrijednosti HIV-1 RNA u plazmi bio je 4,8 log10 kopija po ml, a medijan početnog broja CD4+ stanica bio je 414 x 106 stanica/l (raspon: 25 do 983 x 106 stanica/l).
The median baseline plasma HIV-1 RNA was 4.81 log10 copies/ml (range: 3.21-6.44).
Medijan početne plazmatske vrijednosti HIV-1 RNK bio je 4,81 log10 kopija/ml (raspon: 3,21-6,44).
The median bosentan and placebo treatment duration was, respectively, 4.5 days (range 0.5–10.0 days) and 4.0 days (range 2.5-6.5 days).
Medijan trajanja liječenja bosentanom bio je 4,5 dana (raspon 0,5-10,0 dana), a placebom 4,0 dana (raspon 2,5-6,5 dana).
The median bosentan and placebo treatment duration was, respectively, 4.5 days (range 0.5–10.0 days) and 4.0 days (range 2.5–6.5 days).
Medijan trajanja liječenja bosentanom bio je 4,5 dana (raspon 0,5-10,0 dana), a placebom 4,0 dana (raspon 2,5-6,5 dana).
The median clearance (CL) of Perjeta was 0.235 litres/day and the median half-life was 18 days.
Medijan klirensa (CL) lijeka Perjeta iznosio je 0,235 litara na dan, a medijan poluvijeka 18 dana.
The median comorbidity score was 8 and 76% of the patients enrolled had a comorbidity score above 6.
Medijan rezultata bodovanja komorbiditeta iznosio je 8, a 76% bolesnika uključenih u ispitivanje imalo je rezultat bodovanja komorbiditeta veći od 6.
The median cumulative dose to treatment discontinuation was more than 1,000 mg/m2 and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks).
Medijan kumulativne doze do prekida liječenja bio je veći od 1000 mg/m2, a medijan vremena do reverzibilnosti retencije tekućine bilo je 16,4 tjedana (u rasponu od 0 do 42 tjedna).
The median cumulative dose to treatment discontinuation was more than 1,000 mg/m² and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks).
Medijan kumulativne doze do prekida liječenja bio je veći od 1000 mg/m2, a medijan vremena do reverzibilnosti retencije tekućine bilo je 16,4 tjedana (u rasponu od 0 do 42 tjedna).
The median daily dose of insulin glargine used prior to hyperglycaemic rescue was 10 units (range 2 to 40 units) at study start and 30 units (range 3 to 230 units) at Week 52.
Medijan dnevne doze inzulina glargina primijenjenog prije uporabe lijekova za hitno ublažavanje hiperglikemije iznosio je 10 jedinica (raspon: 2 do 40 jedinica) na početku ispitivanja te 30 jedinica (raspon 3 do 230 jedinica) nakon 52 tjedna.
The median DOR for all subjects was 12.5 months (12.5 months for SLL subjects, and not reached for FL, LPL/WM and MZL subjects).
Medijan DOR-a za sve ispitanike iznosio je 12,5 mjeseci (12,5 mjeseci za ispitanike s SLL, a za ispitanike s FL, LPL/WM i MZL nije dostignut).
The median dose of thalidomide was 217 mg and >40% of patients received 9 cycles.
Medijan doze talidomida iznosio je 217 mg i > 40% bolesnika primilo je 9 ciklusa.
The median dose per injection to maintain haemostasis during surgery was 58.3 (range 45-102) IU/kg.
Medijan doze po injekciji za održavanje hemostaze tijekom kirurškog zahvata iznosio je 58,3 (raspon: 45-102) IU/kg.
The median dose per injection to treat a bleeding episode was 27.35 (interquartile range 22.73-32.71) IU/kg.
Medijan doze po injekciji za liječenje epizode krvarenja iznosio je 27,35 (interkvartilni raspon: 22,73-32,71) IU/kg.
The median dose per injection to treat a bleeding episode was 49.69 (interquartile range 29.41-56.82) IU/kg.
Medijan doze po injekciji za liječenje epizode krvarenja iznosio je 49,69 (interkvartilni raspon: 29,41-56,82) IU/kg.